CHARACTERISTICS OF PREP USERS ATTENDING LONDON SEXUAL AND REPRODUCTIVE HEALTH CLINIC POST-LOCKDOWN

ABSTRACT

Introduction With the advent of COVID, PrEP services and supplies were disrupted. We audited from April 2021 as restrictions were coming to an end. Methods Retrospective case note analysis for those attending a London GU/SRH clinic from 12th April 2021. Basic demographics and clinical parameters were collected and analysed using STATA 13. Results 75 records were returned. Median age was 34 years (IQR 28-39) with 89% (67/75) identifying as male and 73% (47/75) as white. 70% (52/75) reported using daily dosing. Only 5% (4/75) reported chemsex in the previous 3 months. 16% (12/75) had an STI diagnosed at this visit, with 33% being a new syphilis diagnosis. Only 48% (36/75) had been fully vaccinated for HPV and 64% (48/75) for Hepatitis B. At baseline, 57% had eGFR >90mls/min and 37% (28/75) between 6-90 mls/min. There were no patients with evidence of renal decline on taking PrEP (defined as loss of >30 mls/ min eGFR). Only 65% (49/75) were coded correctly. Conclusion The PrEP cohort we are seeing are young, predominately MSM but with an appreciable minority of female and trans patients (10%). Low rates of chemsex and comparatively low rates of STI's indicate a lower risk population than compared to the PROUD study. This may be a result of more MSM attending for PrEP, and not just those who are very high risk of HIV acquisition. We need to ensure vaccination against HPV and HBV are prioritised and ensure correct coding to be able to monitor the number of people starting PrEP.